RADIANCE CAP is a non-randomized study designed to allow for continued access to ultrasound renal denervation therapy via the Paradise System, and to allow for the on-going collection of safety and effectiveness data in subjects with uncontrolled hypertension despite the prescription of antihypertensive medications.

Inclusion Criteria:

• Average office BP ≥140/90 mmHg at screening visit despite taking stables doses of antihypertensive medications for at least 4 weeks prior to consent
• Documented daytime ABP ≥135/85 mmHg following 4 week run-in/standardization period on antihypertensive medication regimen

Exclusion Criteria:

• Renal artery anatomy ineligible for treatment
• Secondary hypertension not including sleep apnea
• Type I diabetes mellitus or uncontrolled Type II diabetes (defined as plasma HbA1c ≥9.0%)
• eGFR <40
• Brachial circumference ≥42 cm
• Any history of cerebrovascular event or severe cardiovascular event within 3 months prior to consent
• Documented repeat (>1) hospitalization for hypertensive crisis within 3 months prior to consent
• Documented confirmed episode(s) of unstable angina within 3 months prior to consent
• Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
• Primary pulmonary hypertension
• Night shift workers
• Pregnant, nursing or planning to become pregnant